Document Detail


Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
MedLine Citation:
PMID:  24852919     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Natalizumab has shown its efficacy in reducing multiple sclerosis (MS) relapses and progression of disability; however, it has been associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML). The differential expression of microRNA (miRNA), the small non-coding RNAs that regulate gene expression, in natalizumab-treated patients has been reported and miRNA have also been described as good candidates for disease biomarkers.
OBJECTIVE: To characterize the effect of natalizumab therapy on the miRNA expression pattern and to search for miRNAs that can predict PML on an individual basis.
METHODS: The expression of 754 microRNAs was measured in blood samples from 19 relapsing-remitting MS patients at three time points during natalizumab therapy, using TaqMan OpenArray panels. Two patients included in this study developed PML after more than 2 years of therapy.
RESULTS: We found that the expression level of three miRNAs (let-7c, miR-125a-5p and miR-642) was affected after 6 months of therapy (t6). Furthermore, we observed a differential expression of another three miRNAs (miR-320, miR-320b and miR-629) between the PML and non-PML groups after 12 months of treatment (t12); and a positive correlation was found between therapy time and the expression of miR-320.
CONCLUSIONS: Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.
Authors:
M Muñoz-Culla; H Irizar; T Castillo-Triviño; M Sáenz-Cuesta; L Sepúlveda; I Lopetegi; A López de Munain; J Olascoaga; Se Baranzini; D Otaegui
Related Documents :
14557489 - Regulation of pten (phosphatase and tensin homolog deleted on chromosome 10) expression...
25189639 - Mrna biomarker detection in liquid-based cytology: a new approach in the prevention of ...
23871289 - Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
11114719 - An alternatively spliced isoform of b-myb is a transcriptional inhibitor.
2683089 - Bas1 has a myb motif and activates his4 transcription only in combination with bas2.
16878159 - Expression of dmp1 in specific differentiated, nonproliferating cells and its regulatio...
22379189 - Hdm2 promotes wip1-mediated medulloblastoma growth.
15244319 - Bound thrombin-induced upregulation of myosin heavy chain isoform, smemb messenger rna ...
8026569 - Alterations in mrna expression of duodenal 1,25-dihydroxyvitamin d3 receptor and vitami...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-5-22
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  -     ISSN:  1477-0970     ISO Abbreviation:  Mult. Scler.     Publication Date:  2014 May 
Date Detail:
Created Date:  2014-5-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© The Author(s), 2014.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multiple sclerosis, solitary sclerosis or something else?
Next Document:  Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment.